Juluca Does Not Cause Weight Loss—It Is Associated With Weight Gain
Juluca (dolutegravir/rilpivirine) is not associated with weight loss; rather, it is associated with weight gain, particularly increases in fat mass. This is consistent with the broader pattern seen with integrase strand transfer inhibitor (INSTI)-based regimens 1.
Evidence from Clinical Trials and Postmarketing Data
The FDA label for Juluca specifically lists "weight increased" as a postmarketing adverse reaction under "Investigations" 2. This directly contradicts any expectation of weight loss with this medication.
In the pivotal SWORD trials that established Juluca's efficacy, weight changes were not a primary endpoint, but subsequent real-world studies have clarified the weight trajectory:
Weight Gain Pattern with Juluca
- A prospective study of 37 patients switching to dolutegravir/rilpivirine showed significant weight gain of 1.8 kg (2.5% increase) at 12 months (P = 0.03) 3
- DXA imaging revealed this weight gain was predominantly fat mass increase: trunk fat increased 7.8%, arm fat 5.6%, and leg fat 6.2%, with no changes in lean mass 3
- Baseline fat mass and CD4 counts were the only factors predicting fat mass gain 3
Context: INSTI-Associated Weight Gain
The 2025 International Antiviral Society-USA guidelines extensively address weight changes with antiretroviral therapy 1:
- Most people on ART experience weight changes of less than 5% body weight, but a minority gain more than 10% 1
- INSTIs (including dolutegravir, a component of Juluca) show greater weight gain compared to boosted protease inhibitors or NNRTIs 1
- Weight gain is more likely in women and Black persons, occurring predominantly within the first year after initiation or switch 1
- Guidelines recommend documenting weight and BMI every 6 months for patients on INSTI-based regimens (evidence rating: AIIa) 1
Rilpivirine Component
While rilpivirine (the other component of Juluca) has also been associated with BMI increase in cohort studies 4, the weight gain observed with the combination appears driven primarily by the dolutegravir component and manifests as fat mass accumulation 3.
Clinical Implications
If a patient on Juluca is experiencing weight loss, this is NOT an expected drug effect and warrants investigation for:
- Poor adherence or malabsorption
- Underlying opportunistic infections
- Malignancy
- Metabolic or endocrine disorders
- Drug interactions affecting absorption
- Other medical conditions
The expected trajectory is weight gain, not loss. Current guidelines do not recommend switching regimens solely due to weight gain because of lack of demonstrated benefit and known toxicities of alternative agents 1. Instead, emphasize lifestyle modifications including diet and exercise, particularly for those at higher risk (women, Black individuals) 1.
Monitoring Recommendations
- Document weight and BMI every 6 months 1
- Consider GLP-1 receptor agonists if significant weight gain occurs and metabolic complications develop 1
- Be aware that switching from Juluca to regimens containing tenofovir disoproxil fumarate may result in weight loss, but this comes with increased renal and bone toxicity risks 1